Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Nov. 7, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Anti-hypertension Therapeutics market. The report identifies the key trends shaping and driving the global Anti-hypertension Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anti-hypertension Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Anti-hypertension Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Anti-hypertension Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Anti-hypertension Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Anti-hypertension Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Anti-hypertension Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Anti-hypertension Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Anti-hypertension Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Anti-hypertension Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Anti-Hypertension Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 12
2.3 Etiology 12
2.4 Signs and Symptoms 12
2.5 Diagnosis 13
2.5.1 Medical History 13
2.5.2 Physical Examination 13
2.5.3 Routine Diagnostic Evaluations 13
2.6 Pathophysiology 14
2.7 Treatment and Management Pattern 15
2.7.1 Angiotensin II Receptor Blockers (ARB) 15
2.7.2 Angiotensin Converting Enzyme (ACE) Inhibitors 16
2.7.3 Diuretics 16
2.7.4 Beta Blockers (BB) 16
2.7.5 Calcium Channel Blockers (CCBs) 16
2.7.6 Direct Renin Inhibitors (DRIs) 17
2.8 GlobalData Pipeline Report Guidance 19
3 Anti-Hypertension Therapeutics - Market Characterization 20
3.1 Overview 20
3.2 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Global 21
3.3 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Global 22
3.4 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - The US 23
3.5 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - The US 24
3.6 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - France 25
3.7 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - France 26
3.8 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Germany 27
3.9 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Germany 28
3.10 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Italy 29
3.11 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Italy 30
3.12 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Spain 31
3.13 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Spain 32
3.14 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - The UK 33
3.15 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - The UK 34
3.16 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Japan 35
3.17 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Japan 36
3.18 Drivers and Barriers for Anti-Hypertension Therapeutics Market 37
3.18.1 Drivers for the Anti-Hypertension Therapeutics Market 37
3.18.2 Barriers for the Anti-Hypertension Therapeutics Market 37
3.19 Opportunity and Unmet Need Analysis 38
3.20 Key Takeaway 39
4 Anti-Hypertension Therapeutics - Competitive Assessment 40
4.1 Overview 40
4.2 Strategic Competitor Assessment 40
4.3 Product Profile for the Major Marketed Products in the Anti-Hypertension Therapeutics 42
4.3.1 Diovan (valsartan) 42
4.3.2 Cozaar (losartan) 43
4.3.3 Vasotec (enalapril) 44
4.3.4 Lotensin (benazepril) 44
4.3.5 Thiazide Diuretics 45
4.3.6 Loop Diuretics 45
4.3.7 Toprol-XL (metoprolol succinate) 46
4.3.8 Tenormin (atenolol) 47
4.3.9 Norvasc (amlodipine) 47
4.3.10 Tekturna (aliskiren) 48
4.4 Key Takeaway 49
5 Anti-Hypertension Therapeutics - Pipeline Assessment 50
5.1 Overview 50
5.2 Strategic Pipeline Assessment 50
5.3 Anti-Hypertension Therapeutics Pipeline - Pipeline by Phases of Development 50
5.3.1 Anti-Hypertension Therapeutics - Phase III and Regulatory Filed Clinical Pipeline 50
5.3.2 Anti-Hypertension Therapeutics - Phase II Clinical Pipeline 51
5.3.3 Anti-Hypertension Therapeutics - Phase I Clinical Pipeline 52
5.3.4 Anti-Hypertension Therapeutics - Pre-Clinical Pipeline 53
5.3.5 Technology Trends Analytic Framework 54
5.4 Anti-Hypertension Therapeutics Market - Clinical Pipeline by Mechanism of Action 56
5.5 Anti-Hypertension Therapeutics - Drugs Under Clinical Development 57
5.6 Anti-Hypertension Therapeutics - Molecule Profile for Promising Drugs Under Clinical Development 57
5.6.1 TAK-491 57
5.6.2 EUR 1000 (Extended release propranalol) 58
5.6.3 Irbesartan/Amlodipine 58
5.6.4 S-474474 59
5.6.5 Telmisartan + Amlodipine + Hydrochlorothiazide 59
5.7 Anti-Hypertension Therapeutics - Other Promising Drugs Under Clinical Development 60
5.7.1 LCZ696 60
5.8 Key Takeaway 60
6 Anti-Hypertension Therapeutics - Clinical Trial Mapping 61
6.1 Clinical Trials by Region/Country 61
6.2 Clinical Trials by Phase 62
6.3 Clinical Trials by Trial Status 63
6.4 Clinical Trials Mapping by Sponsors 64
6.5 Clinical Trials Mapping by Prominent Sponsors 65
6.6 Top Companies Participating in Anti-Hypertension Therapeutics Clinical Trials 66
7 Anti-Hypertension Therapeutics - Strategic Assessment 67
7.1 Key Events Affecting the Future Market 67
7.2 Implications for Future Market Competition 67
8 Anti-Hypertension Therapeutics - Future Players 69
8.1 Introduction 69
8.2 Company Profiles 70
8.2.1 Takeda Pharmaceutical Company Limited 70
8.2.2 Aptalis 72
8.2.3 Novartis AG 73
8.2.4 Sanofi 74
8.3 Other Companies in the Anti-Hypertension Therapeutics Market 76
9 Anti-Hypertension Therapeutics - Licensing and Partnership Deals 79
10 Anti-Hypertension Therapeutics - Appendix 83
10.1 Market Definitions 83
10.2 Abbreviations 83
10.3 Methodology 85
10.3.1 Coverage 85
10.3.2 Secondary Research 85
10.3.3 Forecasting 86
10.3.4 Primary Research 88
10.3.5 Expert Panel Validation 88
10.4 Contact Us 88
10.5 Disclaimer 88
10.6 Bibliography 89
List of Tables
Table 1: Classification of BP 7
Table 2: Recommendations for Follow-up Based on Initial BP Measurements for Adults Without Acute End-Organ Damage 8
Table 3: Complications of Various Types of Hypertension 11
Table 4: Major Risk Factors for Developing Hypertension 12
Table 5: Baseline Blood Tests Recommended by JNC-7 13
Table 6: Clinical Implications of Abnormal Laboratory Tests 14
Table 7: Risk Stratification of BP to Quantify Prognosis 18
Table 8: Major Therapeutic Classes of Anti-Hypertension Drugs 18
Table 9: Anti-Hypertension Therapeutics Market, Global, Revenue, ($bn), 2005 - 2010 21
Table 10: Anti-Hypertension Therapeutics Market, Global, Forecast ($bn), 2010 - 2018 22
Table 11: Anti-Hypertension Therapeutics Market, The US, Revenue ($bn), 2005 - 2010 23
Table 12: Anti-Hypertension Therapeutics Market, The US, Forecast ($bn), 2010 - 2018 24
Table 13: Anti-Hypertension Therapeutics Market, France, Revenue ($bn), 2005 - 2010 25
Table 14: Anti-Hypertension Therapeutics Market, France, Forecast ($bn), 2010 - 2018 26
Table 15: Anti-Hypertension Therapeutics Market, Germany, Revenue ($bn), 2005 - 2010 27
Table 16: Anti-Hypertension Therapeutics Market, Germany, Forecast ($bn), 2010 - 2018 28
Table 17: Anti-Hypertension Therapeutics Market, Italy, Revenue ($bn), 2005 - 2010 29
Table 18: Anti-Hypertension Therapeutics Market, Italy, Forecast ($bn), 2010 - 2018 30
Table 19: Anti-Hypertension Therapeutics Market, Spain, Revenue ($bn), 2005 - 2010 31
Table 20: Anti-Hypertension Therapeutics Market, Spain, Forecast ($bn), 2010 - 2018 32
Table 21: Anti-Hypertension Therapeutics Market, The UK, Revenue ($bn), 2005 - 2010 33
Table 22: Anti-Hypertension Therapeutics Market, The UK, Forecast ($bn), 2010 - 2018 34
Table 23: Anti-Hypertension Therapeutics Market, Japan, Revenue ($bn), 2005 - 2010 35
Table 24: Anti-Hypertension Therapeutics Market, Japan, Forecast ($bn), 2010 - 2018 36
Table 25: Anti-Hypertension Therapeutics - Phase III and Regulatory Filed Pipeline, 2011 50
Table 26: Anti-Hypertension Therapeutics - Phase II Clinical Pipeline, 2011 51
Table 27: Anti-Hypertension Therapeutics - Phase I Clinical Pipeline, 2011 52
Table 28: Anti-Hypertension Therapeutics - Pre-Clinical Pipeline, 2011 53
Table 29: Anti-Hypertension Therapeutics - Most Promising Drugs Under Clinical Development, 2010 57
Table 30: Anti-Hypertension Therapeutics Market, Clinical Trials by Region/Country, (Number), 2011 61
Table 31: Anti-Hypertension Therapeutics Market, Clinical Trials by Phase, 2011 62
Table 32: Anti-Hypertension Therapeutics Market, Clinical Trials by Trial Status, 2011 63
Table 33: Anti-Hypertension Therapeutics Market, Clinical Trials by Overall Sponsors, 2011 64
Table 34: Anti-Hypertension Therapeutics Market, Clinical Trials by Prominent Sponsors, 2011 65
Table 35: Anti-Hypertension Therapeutics Market, Companies Participating in Clinical Trials, 2011 66
Table 36: Takeda - Anti-Hypertension Pipeline Products, 2011 71
Table 37: Aptalis - Cardiovascular Pipeline Products, 2011 73
Table 38: Novartis AG - Anti-Hypertension Pipeline Products, 2011 74
Table 39: Sanofi - Anti-Hypertension Pipeline Products, 2011 75
Table 40: Other Companies in the Anti-Hypertension Therapeutics Market 76
Table 41: Anti-Hypertension Therapeutics Market, Global, Deals, 2011 79
List of Figures
Figure 1: Stages of BP 8
Figure 2: Classification of BP and Types of Hypertension 9
Figure 3: Common Factors Leading to Secondary Hypertension 10
Figure 4: Pathophysiology of Essential Hypertension 14
Figure 5: Renin Angiotensin-Aldosterone System (RAAS) for Regulation of High BP 15
Figure 6: Treatment Algorithm for Hypertension 17
Figure 7: Anti-Hypertension Therapeutics Market, Global, Revenue ($bn), 2005 - 2010 21
Figure 8: Anti-Hypertension Therapeutics Market, Global, Forecast ($bn), 2010 - 2018 22
Figure 9: Anti-Hypertension Therapeutics Market, The US, Revenue ($bn), 2005 - 2010 23
Figure 10: Anti-Hypertension Therapeutics Market, The US, Forecast ($bn), 2010 - 2018 24
Figure 11: Anti-Hypertension Therapeutics Market, France, Revenue ($bn), 2005 - 2010 25
Figure 12: Anti-Hypertension Therapeutics Market, France, Forecast ($bn), 2010 - 2018 26
Figure 13: Anti-Hypertension Therapeutics Market, Germany, Revenue ($bn), 2005 - 2010 27
Figure 14: Anti-Hypertension Therapeutics Market, Germany, Forecast ($bn), 2010 - 2018 28
Figure 15: Anti-Hypertension Therapeutics Market, Italy, Revenue ($bn), 2005 - 2010 29
Figure 16: Anti-Hypertension Therapeutics Market, Italy, Forecast ($bn), 2010 - 2018 30
Figure 17: Anti-Hypertension Therapeutics Market, Spain, Revenue ($bn), 2005 - 2010 31
Figure 18: Anti-Hypertension Therapeutics Market, Spain, Forecast ($bn), 2010 - 2018 32
Figure 19: Anti-Hypertension Therapeutics Market, The UK, Revenue ($bn), 2005 - 2010 33
Figure 20: Anti-Hypertension Therapeutics Market, The UK, Forecast ($bn), 2010 - 2018 34
Figure 21: Anti-Hypertension Therapeutics Market, Japan, Revenue ($bn), 2005 - 2010 35
Figure 22: Anti-Hypertension Therapeutics Market, Japan, Forecast ($bn), 2010 - 2018 36
Figure 23: Opportunity and Unmet Need in the Anti-Hypertension Therapeutics Market, 2011 39
Figure 24: Strategic Competitor Assessment of the Marketed Products for Anti-Hypertension, 2011 41
Figure 25: Anti-Hypertension Therapeutics Pipeline by Phase of Development, 2011 50
Figure 26: Anti-Hypertension Therapeutics - Technology Trends Analytics Framework 54
Figure 27: Anti-Hypertension Therapeutics - Technology Trends Analytics Framework - Description, 2011 55
Figure 28: Anti-Hypertension Therapeutics - Pipeline by Mechanism of Action, 2011 56
Figure 29: Anti-Hypertension Therapeutics Market, Clinical Trials by Region/Country, (Number), 2011 61
Figure 30: Anti-Hypertension Therapeutics Market, Clinical Pipeline by Phase, (%), 2011 62
Figure 31: Anti-Hypertension Therapeutics Market, Clinical Trials by Trial Status, (%), 2011 63
Figure 32: Anti-Hypertension Therapeutics Market, Clinical Trials by Overall Sponsors, (%), 2011 64
Figure 33: Anti-Hypertension Therapeutics Market, Clinical Trials by Prominent Sponsors, (%), 2011 65
Figure 34: Anti-Hypertension Therapeutics Market, Companies Participating in Clinical Trials, 2011 66
Figure 35: Anti-Hypertension Therapeutics, Global, Key Events Impacting the Future Market, 2011 67
Figure 36: Implications for Future Market Competition in the Anti-Hypertension Therapeutics Market, 2011 67
Figure 37: Anti-Hypertension Therapeutics Market - Pipeline by Company, 2011 69
Figure 38: GlobalData Market Forecasting Model 87
Companies Mentioned
Takeda Pharmaceutical Company Limited
Aptalis
Novartis AG
Sanofi
To order this report:
Pathology Industry: Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Pathology Business News
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article